CL2014002728A1 - Composicion farmaceutica que comprende un agente reductor de urato que es un compuesto fenil-metil-fenoxi sustituido tal como halofenato, acido halofenico o sus sales y un agente antiinflamatorio tal como colquicina; kit que comprende dicha composicion; y metodo para tratar una erupcion de gota y la hiperuricemia en la gota. - Google Patents
Composicion farmaceutica que comprende un agente reductor de urato que es un compuesto fenil-metil-fenoxi sustituido tal como halofenato, acido halofenico o sus sales y un agente antiinflamatorio tal como colquicina; kit que comprende dicha composicion; y metodo para tratar una erupcion de gota y la hiperuricemia en la gota.Info
- Publication number
- CL2014002728A1 CL2014002728A1 CL2014002728A CL2014002728A CL2014002728A1 CL 2014002728 A1 CL2014002728 A1 CL 2014002728A1 CL 2014002728 A CL2014002728 A CL 2014002728A CL 2014002728 A CL2014002728 A CL 2014002728A CL 2014002728 A1 CL2014002728 A1 CL 2014002728A1
- Authority
- CL
- Chile
- Prior art keywords
- gout
- composition
- halophene
- halophenate
- hyperuricemia
- Prior art date
Links
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 title 2
- 201000005569 Gout Diseases 0.000 title 2
- -1 phenyl-methyl-phenoxy compound Chemical class 0.000 title 2
- 208000010201 Exanthema Diseases 0.000 title 1
- 201000001431 Hyperuricemia Diseases 0.000 title 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 229940121363 anti-inflammatory agent Drugs 0.000 title 1
- 239000002260 anti-inflammatory agent Substances 0.000 title 1
- 239000003638 chemical reducing agent Substances 0.000 title 1
- 229960001338 colchicine Drugs 0.000 title 1
- 201000005884 exanthem Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 206010037844 rash Diseases 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261624186P | 2012-04-13 | 2012-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014002728A1 true CL2014002728A1 (es) | 2015-06-19 |
Family
ID=49325641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014002728A CL2014002728A1 (es) | 2012-04-13 | 2014-10-10 | Composicion farmaceutica que comprende un agente reductor de urato que es un compuesto fenil-metil-fenoxi sustituido tal como halofenato, acido halofenico o sus sales y un agente antiinflamatorio tal como colquicina; kit que comprende dicha composicion; y metodo para tratar una erupcion de gota y la hiperuricemia en la gota. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20130274331A1 (enExample) |
| EP (1) | EP2836209A4 (enExample) |
| JP (1) | JP2015512948A (enExample) |
| KR (1) | KR20150002799A (enExample) |
| CN (1) | CN104602686A (enExample) |
| AU (1) | AU2013245675B2 (enExample) |
| CA (1) | CA2870014A1 (enExample) |
| CL (1) | CL2014002728A1 (enExample) |
| EA (1) | EA028495B1 (enExample) |
| HK (1) | HK1204913A1 (enExample) |
| IL (1) | IL235154A0 (enExample) |
| MX (1) | MX2014012376A (enExample) |
| PH (1) | PH12014502282A1 (enExample) |
| SG (1) | SG11201406495UA (enExample) |
| WO (1) | WO2013155478A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2900740T3 (es) | 2012-11-02 | 2022-03-18 | Murray & Poole Entpr Ltd | Tratamiento o prevención de episodios cardiovasculares mediante la administración de colchicina |
| WO2014170755A2 (en) | 2013-04-16 | 2014-10-23 | Murray And Poole Enterprises Limited | Sustained-release formulations of colchicine and methods of using same |
| US9907751B2 (en) | 2016-03-10 | 2018-03-06 | RxOMEG Therapeutics LLC | Composition and method of use of colchicine oral liquid |
| JP2023035118A (ja) * | 2021-08-31 | 2023-03-13 | 国立大学法人広島大学 | 体液サンプリング容器 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262118B1 (en) * | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
| US7576131B2 (en) * | 1999-06-04 | 2009-08-18 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
| CA2716860C (en) * | 2008-03-13 | 2017-08-29 | Wellstat Therapeutics Corporation | Compounds and method for reducing uric acid |
| US20090232745A1 (en) * | 2008-03-14 | 2009-09-17 | Intelliherb, Inc. | Licorice lollipop that inhibits dental caries formation |
| US20100137235A1 (en) * | 2008-10-15 | 2010-06-03 | Mutual Pharmaceutical Company, Inc. | Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics |
| US9060987B2 (en) * | 2011-11-04 | 2015-06-23 | Cymabay Therapeutics, Inc. | Methods for treating gout flares |
| DK2775836T3 (en) * | 2011-11-04 | 2018-12-03 | Cymabay Therapeutics Inc | PROCEDURES FOR TREATING GIG RETURN |
| CA2859689C (en) * | 2011-11-04 | 2018-05-22 | Cymabay Therapeutics, Inc. | Methods for treating gout in patient subpopulations |
| CN109908124A (zh) * | 2011-11-04 | 2019-06-21 | 西玛贝医药公司 | 利用卤芬酯或卤芬酸以及第二尿酸降低剂治疗痛风患者中高尿酸血症的方法 |
-
2013
- 2013-04-12 CN CN201380030570.9A patent/CN104602686A/zh active Pending
- 2013-04-12 SG SG11201406495UA patent/SG11201406495UA/en unknown
- 2013-04-12 MX MX2014012376A patent/MX2014012376A/es unknown
- 2013-04-12 US US13/862,262 patent/US20130274331A1/en not_active Abandoned
- 2013-04-12 EP EP13776027.8A patent/EP2836209A4/en not_active Withdrawn
- 2013-04-12 CA CA2870014A patent/CA2870014A1/en not_active Abandoned
- 2013-04-12 KR KR20147031687A patent/KR20150002799A/ko not_active Withdrawn
- 2013-04-12 HK HK15103663.3A patent/HK1204913A1/xx unknown
- 2013-04-12 WO PCT/US2013/036474 patent/WO2013155478A1/en not_active Ceased
- 2013-04-12 AU AU2013245675A patent/AU2013245675B2/en not_active Ceased
- 2013-04-12 JP JP2015505961A patent/JP2015512948A/ja active Pending
- 2013-04-12 EA EA201491870A patent/EA028495B1/ru not_active IP Right Cessation
-
2014
- 2014-10-10 CL CL2014002728A patent/CL2014002728A1/es unknown
- 2014-10-10 PH PH12014502282A patent/PH12014502282A1/en unknown
- 2014-10-19 IL IL235154A patent/IL235154A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20130274331A1 (en) | 2013-10-17 |
| PH12014502282A1 (en) | 2014-12-15 |
| JP2015512948A (ja) | 2015-04-30 |
| WO2013155478A1 (en) | 2013-10-17 |
| MX2014012376A (es) | 2015-06-05 |
| EP2836209A4 (en) | 2015-11-25 |
| HK1204913A1 (en) | 2015-12-11 |
| SG11201406495UA (en) | 2014-11-27 |
| CN104602686A (zh) | 2015-05-06 |
| EA028495B1 (ru) | 2017-11-30 |
| IL235154A0 (en) | 2014-12-31 |
| KR20150002799A (ko) | 2015-01-07 |
| EA201491870A1 (ru) | 2015-03-31 |
| AU2013245675B2 (en) | 2017-02-09 |
| AU2013245675A1 (en) | 2014-10-30 |
| CA2870014A1 (en) | 2013-10-17 |
| EP2836209A1 (en) | 2015-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014000183A1 (es) | Formulación farmacéutica que contienen anticuerpos anti-pcsk9; metodo para preparar dicha formulación. | |
| CL2015000167A1 (es) | Composición herbicida que comprende ácido 4-amino-3-cloro-5-fluoro-6-(4-cloro-2-fluoro-3-metoxifenilo) piridina-2-carboxílico o un derivado del mismo y un inhibidor de la protoporfirinógeno oxidasa; y método para controlar vegetación indeseable. | |
| CL2014000487A1 (es) | Composicion de concentrado en suspension acuosa que comprende acido s-(+)-abscisico con o sin una citoquinina; y metodo para tratar una semilla. | |
| CL2012003548A1 (es) | Composicion farmaceutica de liberacion modificada que comprende esferas de liberacion inmediata y esferas de liberacion demorada de acido 2-[3-ciano-4-(2-metilpropoxi)fenil]-4-metiltiazol-5-carboxilico (febuxostat), inhibidor selectivo de xantina oxidorreductasa; forma de dosificacion; y metodo de tratamiento para gota, entre otros. | |
| CL2014000645A1 (es) | Composicion farmaceutica que comprende a) un ciclopolisacarido tal como una ciclodextrina y b) un compuesto derivado de acido hidroxamico y sus sales, util para tratar una enfermedad neoplasica o una enfermedad inmunitaria. | |
| CR20120413A (es) | Derivados de fumarato de ácido graso y sus usos | |
| PL2444081T3 (pl) | Kompozycja do leczenia chorób zapalnych, zawierająca kwas bosweliowy i kannabidiol | |
| CL2012002627A1 (es) | Metodos para aumentar la tolerancia al estres abiotico y/o reducir las consecuencias del estres abiotico en plantas que comprende ponerla en contacto con una composicion que contiene acido dicarboxilico o un derivado. | |
| CL2013002166A1 (es) | Compuesto correspondiente a la sal de magnesio del acido (s)-alfa-etoxi-4-[2-metil-5-[4-metiltiofenil-1h-pirrol-1-il]etoxi]bencenpropanoico; composicion farmaceutica que lo comprende; y uso para el tratamiento de lipodistrofia. | |
| CL2013001947A1 (es) | Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona. | |
| CL2014003511A1 (es) | Compuesto 2-(1-(4-amino-3-(3-fluoro-4-isopropoxifenil)-1h-pirazolo[3,4-d]pirimidin-1-il)etil)-6-fluoro-3-(3-fluorofenil)-4h-cromen-4-ona y sus sales, inhibidor selectivo de cinasas delta p13k; composicion farmaceutica; uso para tratar una enfermedad o trastorno tal como cancer, trastorno oseo, enfermedad inflamatoria, inmunitaria, metabolica, entre otras. | |
| EP2389221C0 (en) | SUSTAINED RELEASE DELIVERY SYSTEM OF ONE OR MULTIPLE AGENTS | |
| CL2014000855A1 (es) | Composicion antimicrobiana que comprende agua, una mezcla de acidos organicos c1-c18, una mezcla de aldehidos c1-c24, acido pelargonico y aldehido; y metodo para prolongar la vida util del agua, alimentos o ingredientes de alimentos. | |
| BR112014030069A2 (pt) | processo para purificar uma composição de ácido furan, e, composição de ácido furan | |
| CL2013000801A1 (es) | Composicion farmaceutica que comprende un inhibidor de rankl y una hormona o un derivado de la misma, y uso del inhibidor rankl para preparar dicha composicion | |
| ES2543957T3 (es) | Nueva composición farmacéutica para el tratamiento de infecciones fúngicas | |
| BR112012026570A2 (pt) | composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado | |
| CL2014001157A1 (es) | Metodo para tratar un ataque de gota que comprende administrar un compuesto de formula (i) y un segundo agente de reduccion de urato. | |
| HUE055470T2 (hu) | Eljárások és kompozíciók a glikolát-oxidáz (HAO1) kettõs szálú RNA általi specifikus gátlására | |
| EP2683373C0 (de) | Orthomolekulares mittel gegen die folgen von alkoholkonsum | |
| BR112013014103A2 (pt) | método para produzir um l-aminoácido | |
| CL2013000237A1 (es) | Composicion farmaceutica que comprende un sirna dirigido a vegfa; y metodo para disminuir la expresion de vegfa in vivo. | |
| CL2013003094A1 (es) | Composiciones activas de antitranspirante que comprende una sal de aluminio y una especie de cation polihidroxioxoaluminio; metodo de fabricacion de la misma; y su uso. | |
| BR112014013213A2 (pt) | composição microbicida, método para fornecer um efeito bactericida a um substrato e uso de uma composição | |
| CL2014000267A1 (es) | Formulacion farmaceutica liquida que comprende ketoprofeno, amitriptilina y oximetazolina; kit farmaceutico; metodo para prevenir o tratar la inflamacion. |